Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Vaxart ( (VXRT) ) has issued an update.
On January 28, 2025, Vaxart announced the appointment of Kevin Finney to its Board of Directors, effective immediately. Finney, with 35 years of executive experience in the healthcare sector, including significant roles at Autobahn Therapeutics and Allergan, is expected to enhance Vaxart’s strategic direction as it advances its oral vaccine platform. Concurrently, Robert A. Yedid resigned from the Board for personal reasons, marking a leadership transition that could influence Vaxart’s future operations.
More about Vaxart
Vaxart is a clinical-stage biotechnology company specializing in the development of oral recombinant vaccines using its proprietary delivery platform. The company’s innovative approach involves vaccines administered via pills that do not require refrigeration, targeting diseases such as coronavirus, norovirus, influenza, and human papillomavirus (HPV).
YTD Price Performance: 1.53%
Average Trading Volume: 1,835,079
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $178.6M
For an in-depth examination of VXRT stock, go to TipRanks’ Stock Analysis page.
